The ability of E1A to reduce tumorigenicity is dependent on the induction of a robust NK cell and T cell anti-tumor immune response [5] and correlates with the ability of E1A to bind the transcriptional co-adaptor molecule p300 or CBP [6]. Here, EP300 is linked to neoplasm.